New ANDA Cases

Federal district court cases that are filed pursuant to the Hatch-Waxman Act

Third Quarter

GENERICally Speaking

This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.

Case Name Date Filed Judge Drug Patent No(s).
Novartis Pharms. Corp. v. MSN Pharms. Inc., 21-0981 (D. Del.) 1-Jul-21 Hon. Leonard P. Stark Kisqali® Femara®
Co-pack (ribociclib / letrozole tablets)
8,324,225
8,415,355
8,685,980
8,962,630
9,416,136
AstraZeneca AB v. Alembic Pharms. Ltd., 21-0982 (D. Del.) 1-Jul-21 Hon. Richard G. Andrews Tagrisso® (osimertinib mesylate tablets) 10,183,020
Teva Branded Pharm. Products R&D, Inc. v. Aurobindo Pharma Ltd., 21-13240 (D.N.J.) 1-Jul-21 Hon. Freda L. Wolfson Austedo® (deutetrabenazine tablets) 8,524,733
9,233,959
9,296,739
9,550,780
9,814,708
10,959,996
Teva Branded Pharm. Products R&D, Inc. v. Lupin Ltd., 21-13247 (D.N.J.) 1-Jul-21 Hon. Freda L. Wolfson Austedo® (deutetrabenazine tablets) 9,233,959
9,296,739
9,550,780
9,814,708
Orexo AB v. Sun Pharm. Indus. Ltd., 21-13320 (D.N.J.) 2-Jul-21 Hon. Zahid N. Quaraishi Zubsolv® (buprenorphine / naloxone sublingual tablets) 10,874,661
10,946,010
Astellas Pharma Inc. v. Alkem Labs. Ltd., 21-0992 (D. Del.) 6-Jul-21 Hon. Joseph F. Bataillon Myrbetriq®
(mirabegron extended-release tablets)
7,342,117
7,982,049
8,835,474
10,842,780
RE44,872
Bayer Healthcare LLC v. Dr. Reddy’s Labs., Inc., 21-0997 (D. Del.) 7-Jul-21 Hon. Leonard P. Stark Nexavar® (sorafenib tosylate tablets) 9,737,488
Bayer Pharma AG v. Taro Pharm. Indus. Ltd., 21-1000 (D. Del.) 7-Jul-21 Hon. Richard G. Andrews Xarelto® (rivaroxaban tablets) 10,828,310
Bayer Pharma AG v. Teva Pharms. USA, Inc., 21-1001 (D. Del.) 7-Jul-21 Hon. Richard G. Andrews Xarelto® (rivaroxaban tablets) 10,828,310
Horizon Medicines LLC v. Torrent Pharma Inc., 21-13396 (D.N.J.) 7-Jul-21 Hon. Stanley R. Chesler Duexis® (ibuprofen / famotidine tablets) 8,067,033
8,067,451
8,309,127
8,318,202
8,449,910
8,501,228
Eli Lilly and Co. v. Radius Health, Inc., 21-1003 (D. Del.) 8-Jul-21 Hon. Colm F. Connolly Tymlos® (abaloparatide for injection) Forteo® (teriparatide for injection) 7,517,334
Merck Sharp & Dohme Corp. v. Annora Pharma Private Ltd., 21-1006 (D. Del.) 9-Jul-21 Hon. Richard G. Andrews Januvia® (sitagliptin phosphate tablets) 7,326,708
Patheon Softgels Inc. v. Strides Pharma Inc., 21-13521 (D.N.J.) 9-Jul-21 Hon. Brian R. Martinotti Naproxen sodium capsules 9,693,978
9,693,979
10,022,344
10,028,925
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., 21-1015 (D. Del.) 13-Jul-21 Hon. Leonard P. Stark Vyondys® 53 (golodirsen for injection) 10,227,590
10,266,827
10,385,092
10,407,461
10,487,106
10,647,741
10,662,217
10,683,322
9,708,361
9,994,851
Vertex Pharms. Inc. v. Lupin Ltd., 21-1019 (D. Del.) 13-Jul-21 Hon. Richard G. Andrews Kalydeco® (ivacaftor tablets) 10,646,481
Merz Pharms., LLC v. MSN Pharms. Inc., 21-1032 (D. Del.) 15-Jul-21 Hon. Richard G. Andrews Cuvposa® (glycopyrrolate oral solution) 7,638,552
7,816,396
Merck Sharp & Dohme Corp. v. Dr. Reddy’s Labs., Inc., 21-1033 (D. Del.) 15-Jul-21 Hon. Richard G. Andrews Janumet XR® (metformin HCl / sitagliptin phosphate extended release tablets) 7,326,708
Fresenius Kabi USA, LLC v. Baxter Healthcare Corp., 21-1040 (D. Del.) 16-Jul-21 Hon. Maryellen Noreika Naropin® (ropivacaine HCl injection) 7,828,787
7,857,802
8,118,802
8,162,915
Neurocrine Biosciences, Inc. v. Lupin Ltd., 21-1042 (D. Del.) 16-Jul-21 Hon. Maryellen Noreika Ingrezza® (valbenazine capsules) 8,039,627
8,357,697
10,065,952
10,844,058
10,851,103
10,851,104
10,857,137
10,857,148
10,874,648
10,906,902
10,906,903
10,912,771
10,919,892
10,940,141
10,952,997
10,993,941
Neurocrine Biosciences, Inc. v. Teva Pharms., Inc., 21-1043 (D. Del.) 16-Jul-21 Hon. Maryellen Noreika Ingrezza® (valbenazine capsules) 10,065,952
10,844,058
10,851,103
10,851,104
10,857,137
10,857,148
10,874,648
10,906,902
10,906,903
10,912,771
10,919,892
10,940,141
10,952,997
Merz Pharms., LLC v. MSN Pharms. Inc., 21-13731 (D.N.J.) 16-Jul-21 Hon. Brian R. Martinotti Cuvposa® (glycopyrrolate oral solution) 7,638,552
7,816,396
Bayer Pharma AG v. Mylan Pharms. Inc., 21-0099 (N.D.W.V.) 22-Jul-21 Hon. Irene M. Keeley Xarelto® (rivaroxaban tablets) 10,828,310
Allergan USA, Inc. v. Alkem Labs. Ltd., 21-1061 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Allergan USA, Inc. v. Aurobindo Pharma Ltd., 21-1062 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Allergan USA, Inc. v. Hetero Labs Ltd., 21-1063 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Allergan USA, Inc. v. MSN Labs. Private Ltd., 21-1064 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Allergan USA, Inc. v. Sun Pharm. Indus. Ltd., 21-1065 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Allergan USA, Inc. v. Zydus Pharms. (USA) Inc., 21-1066 (D. Del.) 23-Jul-21 Hon. Richard G. Andrews Viberzi® (eluxadoline tablets) 11,007,179
Neurocrine Biosciences, Inc. v. Crystal Pharm. (Suzhou) Co., Ltd., 21-1067 (D. Del.) 23-Jul-21 Hon. Maryellen Noreika Ingrezza® (valbenazine capsules) 10,065,952
10,844,058
10,851,103
10,851,104
10,857,137
10,857,148
10,874,648
10,906,902
10,906,903
10,912,771
10,919,892
10,940,141
10,952,997
Eli Lilly and Co. v. Sun Pharm. Indus. Ltd., 21-1092 (D. Del.) 28-Jul-21 Hon. Colm F. Connolly Forteo® (teriparatide for injection) 7,517,334
Supernus Pharms., Inc. v. Torrent Pharms. Ltd., 21-14268 (D.N.J.) 28-Jul-21 Hon. Freda L. Wolfson Trokendi XR® (topiramate extended-release capsues) 8,298,576
8,298,580
8,663,683
8,877,248
8,889,191
8,992,989
9,549,940
9,555,004
9,622,983
10,314,790
Jazz Pharms. Ireland Ltd. v. Lupin Ltd., 21-14271 (D.N.J.) 28-Jul-21 Hon. Stanley R. Chesler Xywav® (calcium, magnesium, potassium, and sodium oxybates oral solution) 8,591,922
8,772,306
8,901,173
9,050,302
9,132,107
9,486,426
10,195,168
10,213,400
10,675,258
10,864,181
Novartis Pharms. Corp. v. MSN Pharms. Inc., 21-1102 (D. Del.) 29-Jul-21 Hon. Leonard P. Stark Kisqali® (ribociclib tablets) 8,324,225
8,415,355
8,685,980
8,962,630
9,416,136
Novartis Pharms. Corp. v. Lupin Inc., 21-1105 (D. Del.) 29-Jul-21 Hon. Leonard P. Stark Rydapt® (midostaurin capsules) 8,575,146
Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Inc., 21-1106 (D. Del.) 29-Jul-21 Hon. Leonard P. Stark Rydapt® (midostaurin capsules) 7,973,031
Novartis Pharms. Corp. v. Lotus Pharm. Co., Ltd., 21-1107 (D. Del.) 29-Jul-21 Hon. Leonard P. Stark Rydapt® (midostaurin capsules) 7,973,031
8,222,244
8,575,146
AstraZeneca AB v. Torrent Pharms. Ltd., 21-1116 (D. Del.) 30-Jul-21 Hon. Richard G. Andrews Brilinta® (ticagrelor tablets) 10,300,065
Neurocrine Biosciences, Inc. v. Zydus Pharms. (USA) Inc., 21-1118 (D. Del.) 30-Jul-21 Hon. Maryellen Noreika Ingrezza® (valbenazine capsules) 10,065,952
10,844,058
10,851,103
10,851,104
10,857,137
10,857,148
10,874,648
10,906,902
10,906,903
10,912,771
10,919,892
10,940,141
10,952,997
Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Inc., 21-14428 (D.N.J.) 30-Jul-21 Hon. Michael A. Shipp Rydapt® (midostaurin capsules) 7,973,031
Neurocrine Biosciences, Inc. v. Zydus Pharms. (USA) Inc., 21-14447 (D.N.J.) 30-Jul-21 Hon. Kevin McNulty Ingrezza® (valbenazine capsules) 10,065,952
10,844,058
10,851,103
10,851,104
10,857,137
10,857,148
10,874,648
10,906,902
10,906,903
10,912,771
10,919,892
10,940,141
10,952,997
Duchesnay Inc. v. Hetero Labs Ltd., 21-1130 (D. Del.) Aug. 3, 2021 Hon. Leonard P. Stark Osphena® (ospemifene tablets) 6,245,819
8,236,861
Jazz Pharms., Inc. v. Avadel Pharms., plc, 21-1138 (D. Del.) Aug. 4, 2021 Hon. Maryellen Noreika Xyrem® (sodium oxybate oral solution) 11,077,079
Astellas Pharma Inc. v. Apotex Inc., 21-1141 (D. Del.) Aug. 5, 2021 Hon. Joseph F. Bataillon Myrbetriq® (mirabegron extended-release tablets) 10,842,780
Janssen Products, L.P. v. MSN Pharms. Inc., 21-14622 (D.N.J.) Aug. 5, 2021 Hon. Zahid N. Quraishi Yondelis® (trabectedin for injection) 8,895,557
7,420,051
Neurocrine Biosciences, Inc. v. Teva Pharms., Inc., 21-1148 (D. Del.) Aug. 6, 2021 Hon. Maryellen Noreika Ingrezza® (valbenazine capsules) 10,993,941
Vyne Therapeutics Inc. v. Padagis Israel Pharms. Ltd., 21-1152 (D. Del.) Aug. 9, 2021 Hon. Colm F. Connolly Amzeeq® (minocycline topical foam) 8,865,139
8,945,516
8,992,896
9,675,700
10,086,080
10,137,200
10,213,512
10,265,404
10,517,882
10,821,187
10,398,641
10,849,847
Janssen Pharms., Inc. v. Mylan Labs. Ltd., 21-15137 (D.N.J.) Aug. 11, 2021 Hon. Zahid N. Quraishi Invega Trinza® (paliperidone palmitate injection) 10,143,693
Merck Sharp & Dohme Corp. v. MSN Pharms. Inc., 21-1172 (D. Del.) Aug. 12, 2021 Hon. Richard G. Andrews Januvia® (sitagliptin phosphate) Janumet® (metformin HCl / sitagliptin phosphate) 7,326,708
Merck Sharp & Dohme Corp. v. Laurus Labs Ltd., 21-1173 (D. Del.) Aug. 12, 2021 Hon. Richard G. Andrews Januvia® (sitagliptin phosphate) 7,326,708
Pfizer Inc. v. Natco Pharma, Inc., 21-1179 (D. Del.) Aug. 16, 2021 Hon. Colm F. Connolly Ibrance® (palbociclib tablets) RE47,739
10,723,730
Biomarin Pharm. Inc. v. Teva Pharms., Inc., 21-15392 (D.N.J.) Aug. 16, 2021 Hon. Esther Salas Kuvan® (sapropterin dihydrochloride tablets) 7,566,462
7,566,714
7,612,073
7,727,987
8,003,126
8,067,416
RE43,797
8,318,745
9,433,624
Nexus Pharms., Inc. v. Nevakar, Inc., 21-15524 (D.N.J.) Aug. 17, 2021 Hon. Renee Marie Bumb Emerphed® (ephedrine sulfate injection) 11,090,278
10,869,845
Baxter Healthcare Corp. v. Par Sterile Products, LLC, 21-1184 (D. Del.) Aug. 18, 2021 Hon. Unassigned Norepinephrine bitartrate in 5% dextrose injection 10,159,657
10,226,436
10,420,735
10,471,026
10,568,850
10,646,458
Endo Ventures Ltd. v. Baxter Healthcare Corp., 21-1186 (D. Del.) Aug. 18, 2021 Hon. Unassigned Norepinephrine bitartrate in 5% dextrose injection 10,226,436
10,420,735
10,471,026
10,568,850
10,646,458
Tolmar Therapeutics, Inc. v. Foresee Pharms. Co., Ltd., 21-15782 (D.N.J.) Aug. 20, 2021 Hon. Julien Xavier Neals Camcevi® (leuprolide for injection) 8,470,359
UCB Inc. v. Cipla Ltd., 21-1229 (D. Del.) Aug. 26, 2021 Hon. Colm F. Connolly Nayzilam® (midazolam nasal spray) 8,217,033
8,809,322
9,289,432
9,687,495
Zogenix, Inc. v. Apotex Inc., 21-1252 (D. Del.) Aug. 30, 2021 Hon. Colm F. Connolly Fintepla® (fenfluramine oral solution) 10,603,290
10,452,815
Eagle Pharms., Inc. v. Slayback Pharma LLC, 21-1256 (D. Del.) Aug. 31, 2021 Hon. Colm F. Connolly Belrapzo® (bendamustine HCl injection) 11,103,483
Astellas US LLC v. Aurobindo Pharma Ltd., 21-1269 (D. Del.) Sept. 3, 2021 Hon. Colm F. Connolly Lexiscan® (regadenoson for injection) 8,106,183
RE47,301
8,524,883
Apotex Inc. v. Auspex Pharms., Inc., IPR2021-01507 (PTAB) Sept. 8, 2021 N/A Austedo® (deutetrabenazine tablets) 8,524,733
AstraZeneca AB v. Changzhou Pharm. Factory, 21-1284 (D. Del.) Sept. 10, 2021 Hon. Richard G. Andrews Brilinta® (ticagrelor tablets) 8,425,934
Supernus Pharms., Inc. v. Lupin Ltd., 21-1293 (D. Del.) Sept. 10, 2021 Hon. Maryellen Noreika Trokendi XR® (topiramate extended-release capsules) 8,298,576
8,298,580
8,663,683
8,877,248
8,889,191
8,992,989
9,549,940
9,555,004
9,622,983
10,314,790
Bausch & Lomb, Inc. v. Slayback Pharma LLC, 21-16766 (D.N.J.) Sept. 10, 2021 Hon. Michael A. Shipp Lumify® (brimonidine tartrate ophthalmic solution) 8,293,742
9,259,425
Supernus Pharms., Inc. v. Zydus Pharms. (USA) Inc., 21-17104 (D.N.J.) Sept. 17, 2021 Hon. Freda L. Wolfson Trokendi XR® (topiramate extended-release capsules) 8,298,576
8,298,580
8,663,683
8,877,248
8,889,191
8,992,989
9,549,940
9,555,004
9,622,983
10,314,790
Supernus Pharms., Inc. v. Zydus Pharms. (USA) Inc., 21-7795 (S.D.N.Y.) Sept. 17, 2021 Hon. Jed S. Rakoff Trokendi XR® (topiramate extended-release capsules) 8,298,576
8,298,580
8,663,683
8,877,248
8,889,191
8,992,989
9,549,940
9,555,004
9,622,983
10,314,790
Novartis Pharms. Corp. v. Alkem Labs. Ltd., 21-1330 (D. Del.) Sept. 20, 2021 Hon. Leonard P. Stark Entresto® (sacubitril / valsartan tablets) 11,096,918
Puma Biotechnology, Inc. v. AstraZeneca Pharms. LP, 21-1338 (D. Del.) Sept. 22, 2021 Hon. Colm F. Connolly Tagrisso® (osimertinib tablets) 10,603,314
10,596,162
Almirall, LLC v. Aleor Dermaceuticals Ltd., 21-17449 (D.N.J.) Sept. 23, 2021 Hon. Madeline Cox Arleo Aczone® (dapsone gel) 9,517,219
Novartis Pharms. Corp. v. Crystal Pharm. (Suzhou) Co., Ltd., 21-1347 (D. Del.) Sept. 24, 2021 Hon. Leonard P. Stark Entresto® (sacubitril / valsartan tablets) 9,517,226
9,937,143
Anacor Pharms., Inc. v. Alkem Labs. Ltd., 21-1348 (D. Del.) Sept. 24, 2021 Hon. Colm F. Connolly Eucrisa® (crisaborole ointment) 8,039,451
8,168,614
8,501,712
9,682,092
Anacor Pharms., Inc. v. Dr. Reddy’s Labs., Ltd., 21-1349 (D. Del.) Sept. 24, 2021 Hon. Colm F. Connolly Eucrisa® (crisaborole ointment) 8,039,451
8,168,614
8,501,712
9,682,092
Anacor Pharms., Inc. v. Macleods Pharms. Ltd., 21-1350 (D. Del.) Sept. 24, 2021 Hon. Colm F. Connolly Eucrisa® (crisaborole ointment) 8,039,451
8,168,614
8,501,712
9,682,092
Anacor Pharms., Inc. v. Padagis Israel Pharms. Ltd., 21-1351 (D. Del.) Sept. 24, 2021 Hon. Colm F. Connolly Eucrisa® (crisaborole ointment) 8,168,614
8,501,712
9,682,092
Anacor Pharms., Inc. v. Teva Pharms. Development, Inc., 21-1353 (D. Del.) Sept. 24, 2021 Hon. Colm F. Connolly Eucrisa® (crisaborole ointment) 8,168,614
8,501,712
9,682,092
Medicure Int’l, Inc. v. Aurobindo Pharma Ltd., 21-17534 (D.N.J.) Sept. 24, 2021 Hon. Kevin McNulty Aggrastat® (tirofiban HCl injection) 6,770,660
Pfizer Inc. v. Apotex Inc., 21-1402 (D. Del.) Sept. 30, 2021 Hon. Colm F. Connolly Chantix® (varenicline tartrate tablets) 6,890,927
7,265,119
Anacor Pharms., Inc. v. Dr. Reddy’s Labs., Ltd., 21-17831 (D.N.J.) Sept. 30, 2021 Hon. Freda L. Wolfson Eucrisa® (crisaborole ointment) 8,039,451
8,168,614
8,501,712
9,682,092
Bristol-Myers Squibb Co. v. Alembic Global Holding SA, 21-17926 (D.N.J.) Sept. 30, 2021 Hon. Kevin McNulty Sprycel® (dasatinib tablets) 7,491,725
8,680,103

Related Publications

Second Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
June 21, 2022
Novartis Pharms. Corp. v. Accord Healthcare, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top